ApicHope Pharmaceutical Co., Ltd

SZSE:300723 Stock Report

Market Cap: CN¥7.4b

ApicHope Pharmaceutical Future Growth

Future criteria checks 5/6

ApicHope Pharmaceutical is forecast to grow earnings and revenue by 85.9% and 21.7% per annum respectively. EPS is expected to grow by 86.4% per annum. Return on equity is forecast to be 11.3% in 3 years.

Key information

85.9%

Earnings growth rate

86.4%

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth rate21.7%
Future return on equity11.3%
Analyst coverage

Low

Last updated22 Nov 2024

Recent future growth updates

Recent updates

Revenues Not Telling The Story For ApicHope Pharmaceutical Co., Ltd (SZSE:300723) After Shares Rise 38%

Oct 09
Revenues Not Telling The Story For ApicHope Pharmaceutical Co., Ltd (SZSE:300723) After Shares Rise 38%

Does ApicHope Pharmaceutical (SZSE:300723) Have A Healthy Balance Sheet?

Jun 27
Does ApicHope Pharmaceutical (SZSE:300723) Have A Healthy Balance Sheet?

ApicHope Pharmaceutical (SZSE:300723) Is Paying Out A Larger Dividend Than Last Year

May 27
ApicHope Pharmaceutical (SZSE:300723) Is Paying Out A Larger Dividend Than Last Year

ApicHope Pharmaceutical's (SZSE:300723) Shareholders Have More To Worry About Than Only Soft Earnings

May 03
ApicHope Pharmaceutical's (SZSE:300723) Shareholders Have More To Worry About Than Only Soft Earnings

Bearish: Analysts Just Cut Their ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Revenue and EPS estimates

May 02
Bearish: Analysts Just Cut Their ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Revenue and EPS estimates

ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet

Mar 15
ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet

Market Participants Recognise ApicHope Pharmaceutical Co., Ltd's (SZSE:300723) Earnings

Feb 27
Market Participants Recognise ApicHope Pharmaceutical Co., Ltd's (SZSE:300723) Earnings

Earnings and Revenue Growth Forecasts

SZSE:300723 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,267383N/A6034
12/31/20252,775369N/A5464
12/31/20242,345165N/A3744
9/30/20241,893-344-416-12N/A
6/30/20242,1502655438N/A
3/31/20242,410174135480N/A
12/31/20232,503185124458N/A
9/30/20232,515307119416N/A
6/30/20232,641341123511N/A
3/31/20232,480322-21480N/A
1/1/20232,280291-130476N/A
9/30/20222,161285-153511N/A
6/30/20222,151344-157540N/A
3/31/20222,200319-176455N/A
12/31/20212,199307-123438N/A
9/30/20212,135317-133388N/A
6/30/20211,978263-163279N/A
3/31/20211,851250-63341N/A
12/31/20201,675226-39275N/A
9/30/20201,640173-51201N/A
6/30/20201,51511778249N/A
3/31/20201,64113828144N/A
12/31/20191,637144175281N/A
9/30/20191,537243223301N/A
6/30/20191,435234169275N/A
3/31/20191,39521924297N/A
12/31/20181,430208-18239N/A
9/30/20181,42618023263N/A
6/30/20181,477167N/A185N/A
3/31/20181,467166N/A186N/A
12/31/20171,380157N/A158N/A
9/30/20171,399156N/A109N/A
12/31/20161,251137N/A146N/A
12/31/20151,02860N/A35N/A
12/31/201479340N/A9N/A
12/31/201350833N/A136N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300723 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 300723 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300723 is expected to become profitable in the next 3 years.

Revenue vs Market: 300723's revenue (21.7% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 300723's revenue (21.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300723's Return on Equity is forecast to be low in 3 years time (11.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y